GAD2 and lymphopenia: Compared with GAD65-alum treatment, teplizumab is a broader immunosuppressive therapy that has some transient yet drastic effects on T cell populations, such as lymphopenia, as well as other adverse effects such as rash, cytokine release syndrome, and increased reactivation of Epstein-Barr virus among immunodeficient patients [44, 45].